肿瘤引流淋巴结免疫抑制微环境形成机制及靶向治疗研究进展
Research Progress on the Formation Mechanism of Immune Suppression Microenvironment in Tumor-Draining Lymph Nodes and Targeted Therapy
DOI: 10.12677/WJCR.2026.161006, PDF,   
作者: 李 行*：重庆理工大学药学与生物工程学院，重庆；周 丽#：金凤实验室，重庆
关键词: 肿瘤引流淋巴结；免疫逃逸；免疫检查点抑制剂；免疫治疗；Tumor-Draining Lymph Nodes； Immune Evasion； Immune Checkpoint Inhibitors； Immunotherapy
摘要: 肿瘤引流淋巴结(TDLN)是抗肿瘤免疫调控的核心部位。TDLN不仅是诱导肿瘤免疫应答的关键场所，更是介导免疫检查点抑制剂响应的重要部位。当前，领域内的研究多聚焦于肿瘤局部免疫抑制微环境的形成机制及其导致免疫治疗耐药的机制及干预策略，而针对TDLN免疫抑制调控网络的系统性探索较为薄弱。然而，越来越多的研究表明，在肿瘤驯化下TDLN内免疫抑制微环境的形成是肿瘤逃逸免疫监视的关键环节：如调节性T细胞、调节性B细胞、调节性树突状细胞等免疫抑制细胞在此构建免疫抑制微环境，直接影响T细胞活化及分化路径，进而驱动肿瘤免疫逃逸，最终显著削弱免疫检查点抑制剂疗效。本文聚焦TDLN这一被忽视的免疫调控关键环节，以其免疫抑制微环境的形成机制为重点，并总结基于TDLN为靶点的治疗策略，为深入理解肿瘤免疫检查点抑制剂疗法的耐药机制、开发新型免疫检查点抑制剂联合治疗策略提供理论依据。
Abstract: Tumor-draining lymph nodes (TDLNs) serve as a central hub for regulating anti-tumor immunity. They are not only key loci for inducing tumor immune responses but also critical sites mediating the efficacy of immune checkpoint inhibitors (ICIs). Currently, most research in the field focuses on the formation mechanisms of the local immunosuppressive tumor microenvironment, as well as the mechanisms underlying immunotherapy resistance and corresponding intervention strategies. However, systematic exploration of the immunosuppressive regulatory network within TDLNs remains insufficient. Nevertheless, a growing body of evidence indicates that the formation of an immunosuppressive microenvironment in TDLNs under tumor conditioning is a pivotal step for tumors to escape immune surveillance. For instance, immunosuppressive cells such as regulatory T cells (Tregs), regulatory B cells (Bregs), and regulatory dendritic cells (DCregs) accumulate here to establish an immunosuppressive microenvironment. This directly impairs T cell activation and differentiation pathways, thereby driving tumor immune evasion and ultimately significantly compromising the therapeutic efficacy of ICIs. Focusing on TDLNs—this overlooked key node in immune regulation—this review emphasizes the formation mechanisms of their immunosuppressive microenvironment and summarizes TDLN-targeted therapeutic strategies. It aims to provide a theoretical basis for a deeper understanding of the resistance mechanisms to tumor ICI therapy and the development of novel combination therapeutic strategies involving ICIs.
文章引用：李行, 周丽. 肿瘤引流淋巴结免疫抑制微环境形成机制及靶向治疗研究进展[J]. 世界肿瘤研究, 2026, 16(1): 41-47. https://doi.org/10.12677/WJCR.2026.161006

参考文献

[1] Fujimura, T., Muto, Y. and Asano, Y. (2022) Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma. International Journal of Molecular Sciences, 23, Article No. 15720. [Google Scholar] [CrossRef] 
[2] Alrabadi, N.N., Abushukair, H.M., Ababneh, O.E., Syaj, S.S., Al-Horani, S.S., Qarqash, A.A., et al. (2021) Systematic Review and Meta-Analysis Efficacy and Safety of Immune Checkpoint Inhibitors in Advanced Melanoma Patients with Anti-PD-1 Progression: A Systematic Review and Meta-Analysis. Clinical and Translational Oncology, 23, 1885-1904. [Google Scholar] [CrossRef] 
[3] Reticker-Flynn, N.E. and Engleman, E.G. (2023) Lymph Nodes: At the Intersection of Cancer Treatment and Progression. Trends in Cell Biology, 33, 1021-1034. [Google Scholar] [CrossRef] 
[4] Campisi, M., Shelton, S.E., Chen, M., Kamm, R.D., Barbie, D.A. and Knelson, E.H. (2022) Engineered Microphysiological Systems for Testing Effectiveness of Cell-Based Cancer Immunotherapies. Cancers, 14, Article No. 3561. [Google Scholar] [CrossRef] 
[5] Peggs, K.S., Quezada, S.A. and Allison, J.P. (2008) Cell Intrinsic Mechanisms of T-Cell Inhibition and Application to Cancer Therapy. Immunological Reviews, 224, 141-165. [Google Scholar] [CrossRef] 
[6] Saddawi-Konefka, R., Schokrpur, S. and Gutkind, J.S. (2024) Let It Be: Preserving Tumor-Draining Lymph Nodes in the Era of Immuno-Oncology. Cancer Cell, 42, 930-933. [Google Scholar] [CrossRef] 
[7] Zhang, F., Bai, H., Gao, R., Fei, K., Duan, J., Zhang, Z., et al. (2020) Dynamics of Peripheral T Cell Clones during PD-1 Blockade in Non-Small Cell Lung Cancer. Cancer Immunology, Immunotherapy, 69, 2599-2611. [Google Scholar] [CrossRef] 
[8] Messmer, J.M., Effern, M. and Hölzel, M. (2023) From Tpex to Tex: A Journey through CD8+ T Cell Responses in Cancer Immunotherapy. Signal Transduction and Targeted Therapy, 8, Article No. 331. [Google Scholar] [CrossRef] 
[9] Gan, L., Lu, T., Lu, Y., Song, H., Zhang, J., Zhang, K., et al. (2024) Endosialin-Positive CAFs Promote Hepatocellular Carcinoma Progression by Suppressing CD8+ T Cell Infiltration. Journal for ImmunoTherapy of Cancer, 12, e009111. [Google Scholar] [CrossRef] 
[10] Huang, Q., Xu, L. and Ye, L. (2025) Functional Subsets of Tumor-Specific CD8+ T Cells in Draining Lymph Nodes and Tumor Microenvironment. Current Opinion in Immunology, 92, Article ID: 102506. [Google Scholar] [CrossRef] 
[11] Toker, A. and Ohashi, P.S. (2019) Expression of Costimulatory and Inhibitory Receptors in FoxP3+ Regulatory T Cells within the Tumor Microenvironment: Implications for Combination Immunotherapy Approaches. Advances in Cancer Research, 144, 193-261.
[12] Fan, J., Ho, H. and Chiang, B. (2024) Characterization of Novel CD8+ Regulatory T Cells and Their Modulatory Effects in Murine Model of Inflammatory Bowel Disease. Cellular and Molecular Life Sciences, 81, Article No. 327. [Google Scholar] [CrossRef] 
[13] Hindley, J.P., Jones, E., Smart, K., Bridgeman, H., Lauder, S.N., Ondondo, B., et al. (2012) T-Cell Trafficking Facilitated by High Endothelial Venules Is Required for Tumor Control after Regulatory T-Cell Depletion. Cancer Research, 72, 5473-5482. [Google Scholar] [CrossRef] 
[14] Saleh, R. and Elkord, E. (2020) Acquired Resistance to Cancer Immunotherapy: Role of Tumor-Mediated Immunosuppression. Seminars in Cancer Biology, 65, 13-27. [Google Scholar] [CrossRef] 
[15] Baba, Y., Saito, Y. and Kotetsu, Y. (2019) Heterogeneous Subsets of B-Lineage Regulatory Cells (Breg Cells). International Immunology, 32, 155-162. [Google Scholar] [CrossRef] 
[16] Matsumura, Y., Watanabe, R. and Fujimoto, M. (2022) Suppressive Mechanisms of Regulatory B Cells in Mice and Humans. International Immunology, 35, 55-65. [Google Scholar] [CrossRef] 
[17] Chen, Q., Lai, L., Chi, X., Lu, X., Wu, H., Sun, J., et al. (2020) CD19+CD24hiCD38hi B Cell Dysfunction in Primary Biliary Cholangitis. Mediators of Inflammation, 2020, Article ID: 3019378. [Google Scholar] [CrossRef] 
[18] Tran Janco, J.M., Lamichhane, P., Karyampudi, L. and Knutson, K.L. (2015) Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis. The Journal of Immunology, 194, 2985-2991. [Google Scholar] [CrossRef] 
[19] Hassannia, H., Ghasemi Chaleshtari, M., Atyabi, F., Nosouhian, M., Masjedi, A., Hojjat-Farsangi, M., et al. (2019) Blockage of Immune Checkpoint Molecules Increases T-Cell Priming Potential of Dendritic Cell Vaccine. Immunology, 159, 75-87. [Google Scholar] [CrossRef] 
[20] Horton, J.D., Knochelmann, H.M., Day, T.A., Paulos, C.M. and Neskey, D.M. (2019) Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy. Trends in Cancer, 5, 208-232. [Google Scholar] [CrossRef] 
[21] Gkountidi, A.O., Garnier, L., Dubrot, J., Angelillo, J., Harlé, G., Brighouse, D., et al. (2021) MHC Class II Antigen Presentation by Lymphatic Endothelial Cells in Tumors Promotes Intratumoral Regulatory T Cell-Suppressive Functions. Cancer Immunology Research, 9, 748-764. [Google Scholar] [CrossRef] 
[22] Sharma, M.D., Baban, B., Chandler, P., Hou, D., Singh, N., Yagita, H., et al. (2007) Plasmacytoid Dendritic Cells from Mouse Tumor-Draining Lymph Nodes Directly Activate Mature Tregs via Indoleamine 2,3-Dioxygenase. Journal of Clinical Investigation, 117, 2570-2582. [Google Scholar] [CrossRef] 
[23] Ibrahim, S.A., Ahmed, A.N.A., Elsersy, H.A. and Darahem, I.M.H. (2020) Elective Neck Dissection in T1/T2 Oral Squamous Cell Carcinoma with N0 Neck: Essential or Not? A Systematic Review and Meta-Analysis. European Archives of Oto-Rhino-Laryngology, 277, 1741-1752. [Google Scholar] [CrossRef] 
[24] Wang, J., Chen, R., Li, J. and Lu, X. (2020) The Individualized Significance of Lymphadenectomy across All Age Groups and Histologies in Malignant Ovarian Germ Cell Tumors. Archives of Gynecology and Obstetrics, 302, 1441-1450. [Google Scholar] [CrossRef] 
[25] Giuliano, A.E., Ballman, K., McCall, L., Beitsch, P., Whitworth, P.W., Blumencranz, P., et al. (2016) Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-Term Follow-Up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Annals of Surgery, 264, 413-420. [Google Scholar] [CrossRef] 
[26] Feng, Y., Lu, Q., Dong, Y., Chen, J., Zhao, Y., Xu, L., et al. (2025) Survival Benefits in Non-Small Cell Lung Cancer during the Immune Check-point Inhibitor Era: Integrating Lymph Node Burden for Prognostic Precision. Translational Lung Cancer Research, 14, 3363-3377. [Google Scholar] [CrossRef] 
[27] Munn, D.H. and Mellor, A.L. (2006) The Tumor-Draining Lymph Node as an Immune-Privileged Site. Immunological Reviews, 213, 146-158. [Google Scholar] [CrossRef] 
[28] Duraiswamy, J., Kaluza, K.M., Freeman, G.J. and Coukos, G. (2013) Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors. Cancer Research, 73, 3591-3603. [Google Scholar] [CrossRef] 
[29] Shi, L.Z., Goswami, S., Fu, T., Guan, B., Chen, J., Xiong, L., et al. (2019) Blockade of CTLA-4 and PD-1 Enhances Adoptive T-Cell Therapy Efficacy in an Icos-Mediated Manner. Cancer Immunology Research, 7, 1803-1812. [Google Scholar] [CrossRef] 
[30] Lorentzen, C.L., Kjeldsen, J.W., Ehrnrooth, E., Andersen, M.H. and Marie Svane, I. (2023) Long-Term Follow-Up of Anti-PD-1 Naïve Patients with Metastatic Melanoma Treated with IDO/PD-L1 Targeting Peptide Vaccine and Nivolumab. Journal for ImmunoTherapy of Cancer, 11, e006755. [Google Scholar] [CrossRef] 
[31] Haynes, C., Graham, L. and Bear, H.D. (2024) Adoptive Immunotherapy with Cells from Tumor-Draining Lymph Nodes Activated and Expanded in Vitro. Methods in Cell Biology, 183, 355-380.
[32] Contreras, A., Beems, M.V., Tatar, A.J., Sen, S., Srinand, P., Suresh, M., et al. (2018) Co-Transfer of Tumor-Specific Effector and Memory CD8+ T Cells Enhances the Efficacy of Adoptive Melanoma Immunotherapy in a Mouse Model. Journal for ImmunoTherapy of Cancer, 6, Article No. 41. [Google Scholar] [CrossRef] 

为你推荐